Calciphylaxis is a rare necrotizing calcifying arteriolopathy, with a poor prognosis, for which there is currently no effective treatment. One of the major challenges of the therapy is normalizing the calcium-phosphate balance. Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.revmed.2008.04.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium Thiosulfate Treatment for Calciphylaxis: Is There an Optimal Duration of Therapy?
Hemodial Int
January 2025
Nephrology Division, Medical School, Universidade de São Paulo, São Paulo, Brazil.
Calciphylaxis is a rare and serious disorder characterized by vascular calcification and occlusion of the microvessels in the dermis, subcutaneous adipose tissue, visceral organs, and musculature. Studies have suggested that the major risk factors for developing calciphylaxis are chronic kidney disease and secondary hyperparathyroidism. Its diagnosis is clinical, and the treatment includes a multidisciplinary approach, although there are no clinical protocols based on randomized clinical trials.
View Article and Find Full Text PDFManaging Calciphylaxis: Insights from Real-World Cases at a Tertiary Academic Center.
Adv Skin Wound Care
January 2025
At University of Michigan Medical School, Ann Arbor, Michigan, United States, Kanika Kochhar, DPM, is Podiatry Fellow; and Brennen O'Dell, DPM, Garneisha Torrence, DPM, MHMS, and Alton Johnson, DPM, DABPM, FACPM, FASPS, CWSP, are Clinical Assistant Professors. Carey Spitler, MSN, NP-C, CWON, is Nurse Practitioner, University of Michigan Health, Michigan Medicine, Ann Arbor. Also at University of Michigan Medical School, Brian Schmidt, DPM, is Clinical Associate Professor.
Calciphylaxis is a rare and potentially fatal condition involving chronic, nonhealing wounds caused by microvascular calcification. There is currently no approved treatment for calciphylaxis, contributing to its devastating impacts on quality of life. In this case series, the authors highlight instances of potentially misdiagnosed calciphylaxis in a cohort of patients and emphasize the importance of accurate diagnosis through multidisciplinary management approaches.
View Article and Find Full Text PDFCharacteristics and prognostic values of abdominal aortic branches calcification in hemodialysis patients.
Ren Fail
December 2025
Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Background: Vascular calcification is highly prevalent and associated with mortality in hemodialysis patients. However, extreme splanchnic arterial calcification in calciphylaxis with poor prognosis raises questions regarding the reliability of previous vascular calcification scoring methods. Therefore, this study aimed to examine the distribution characteristics of abdominal aortic branch calcification and identify a more reliable predictor of mortality in hemodialysis patients.
View Article and Find Full Text PDFCourse and treatment of severe osteoporosis complicated by calciphylaxis: a case report.
JBMR Plus
January 2025
Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, 162-8666, Japan.
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare disorder with many unknown treatment and diagnostic aspects. It is characterized by calcification and thrombosis of small blood vessels. This disease leads to progressive skin calcification, necrotizing ulcers, and infections and is associated with a high mortality rate.
View Article and Find Full Text PDFCalcific Uremic Arteriolopathy (CUA) Among Malaysian Dialysis Patients: Clinical Characteristics, Treatment, and Outcomes.
Cureus
November 2024
Department of Nephrology, Universiti Malaya Medical Centre, Kuala Lumpur, MYS.
Background Calcific uremic arteriolopathy (CUA) is a rare but debilitating disease affecting patients with kidney disease. Reported risk factors of CUA in the literature include female sex, obesity, diabetes mellitus, and vitamin K antagonists' (VKAs) usage. CUA prevalence in Malaysia is unknown and has not been reported before.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!